Premium
Skeletal involvement in Gaucher disease: An observational multicenter study of prognostic factors in the Argentine Gaucher disease patients
Author(s) -
Drelichman Guillermo,
Fernández Escobar Nicolás,
Basack Nora,
Aversa Luis,
Larroude María Silvia,
Aguilar Gabriela,
Szlago Marina,
Sche Andrea,
Fynn Alcyra,
Cuello María Fernanda,
Aznar Marcela,
Fernández Ramiro,
Ruiz Alba,
Reichel Paola,
Guelbert Norberto,
Robledo Hugo,
Watman Nora,
Bolesina Moira,
Elena Graciela,
Veber S. Ernesto,
Pujal Graciela,
Galván Graciela,
Chain Juan José,
Arizo Adriana,
Bietti Julieta,
Bar Daniel,
Dragosky Marta,
Marquez Marisa,
Feldman Leonardo,
Muller Katja,
Zirone Sandra,
Buchovsky Greogorio,
Lanza Victoria,
Sanabria Alba,
Fernández Ignacio,
Jaureguiberry Rossana,
Contte Marcelo,
Barbieri María Angie,
Maro Alejandra,
Zárate Graciela,
Fernández Gabriel,
Rapetti María Cristina,
Donato Hugo,
Degano Adriana,
Kantor Gustavo,
Albina Roberto,
Á;lvarez Bollea María,
Brun María,
Bacciedoni Viviana,
Del Río Francis,
Soberón Bárbara,
Boido Nazario,
Schweri Maya,
Borchichi Sandra,
Welsh Victoria,
Corrales Marcela,
Cedola Alejandra,
Carvani Analía,
Diez Blanca,
Richard Lucía,
Baduel Ccecilia,
Nuñez Gabriela,
Colimodio Rubén,
Barazzutti Lucía,
Medici Hugo,
Meschengieser Susana,
Damiani Germán,
Nucifora María,
Girardi Beatriz,
Gómez Sergio,
Papucci Maura,
Verón David,
Quiroga Luis,
Carro Gustavo,
De Ambrosio Patricia,
Ferro José,
Pujol Marcelo,
Castella Cristina Cabral,
Franco Liliana,
Nisnovich Gisela,
Veloso María,
Pacheco Isabel,
Savarino Mario,
Marino Andrés,
Saavedra José Luis
Publication year - 2016
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.24486
Subject(s) - medicine , enzyme replacement therapy , disease , bone pain , bone marrow , avascular necrosis , bone disease , bone remodeling , gastroenterology , surgery , osteoporosis , femoral head
Patients with Gaucher type 1 (GD1) throughout Argentina were enrolled in the Argentine bone project to evaluate bone disease and its determinants. We focused on presence and predictors of bone lesions (BL) and their relationship to therapeutic goals (TG) with timing and dose of enzyme replacement therapy (ERT). A total of 124 patients on ERT were enrolled in a multi‐center study. All six TG were achieved by 82% of patients: 70.1% for bone pain and 91.1% for bone crisis. However, despite the fact that bone TGs were achieved, residual bone disease was present in 108 patients on ERT (87%) at time 0. 16% of patients showed new irreversible BL (bone infarcts and avascular osteonecrosis) despite ERT, suggesting that they appeared during ERT or were not detected at the moment of diagnosis. We observed 5 prognostic factors that predicted a higher probability of being free of bone disease: optimal ERT compliance; early diagnosis; timely initiation of therapy; ERT initiation dose ≥45 UI/kg/EOW; and the absence of history of splenectomy. Skeletal involvement was classified into 4 major phenotypic groups according to BL: group 1 (12.9%) without BL; group 2 (28.2%) with reversible BL; group 3 (41.9%) with reversible BL and irreversible chronic BL; and group 4 (16.9%) with acute irreversible BL. Our study identifies prognostic factors for achieving best therapeutic outcomes, introduces new risk stratification for patients and suggests the need for a redefinition of bone TG. Am. J. Hematol. 91:E448–E453, 2016. © 2016 Wiley Periodicals, Inc.